Drug intelligence / Profile preview

VET3-TGI

Development stage: Phase 1
Lead developer: KaliVir Immunotherapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes, Gene Therapies
Administration: Intravenous, Intravesical

Overview

VET3-TGI is a novel oncolytic immunotherapy developed by KaliVir Immunotherapeutics. It utilizes a genetically engineered vaccinia virus platform (Vaccinia Enhanced Template, or VET) to selectively infect and kill tumor cells. The virus delivers an immuno-stimulatory payload consisting of interleukin-12 (IL-12) and a transforming growth factor beta (TGF-β) inhibitor. Modifications for the expression of CXCR3 enhance trafficking to tumors and promote anti-tumor immune responses. It is currently being evaluated in Phase 1/1b clinical trials for advanced solid tumors as both monotherapy and in combination with checkpoint inhibitors.

Targets

IL-12R (Interleukin-12 receptor)CCR3 (C-C chemokine receptor type 3)

Beyond the preview

Go deeper on VET3-TGI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VET3-TGI.

Explore the full profile